Development of gene transfer for induction of antigen-s

Molecular Therapy - Methods and Clinical Development
1, 14013
DOI: 10.1038/mtm.2014.13

Citation Report

#	Article	IF	Citations
1	Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnology Journal, 2015, 13, 1023-1032.	8.3	51
2	Gene therapy for hemophilia. Frontiers in Bioscience - Landmark, 2015, 20, 556-603.	3.0	51
3	Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases. Digestive Diseases, 2015, 33, 70-74.	1.9	19
4	Gene therapy for immune tolerance induction in hemophilia with inhibitors. Journal of Thrombosis and Haemostasis, 2016, 14, 1121-1134.	3.8	54
5	Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 15053.	4.1	44
6	Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16063.	4.1	54
7	Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16083.	4.1	36
8	Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Molecular Therapy, 2016, 24, 1042-1049.	8.2	91
9	A genome editing primer for the hematologist. Blood, 2016, 127, 2525-2535.	1.4	23
10	Immune Modulation and Prevention of Autoimmune Disease by Repeated Sequences from Parasites Linked to Self Antigens. Journal of NeuroImmune Pharmacology, 2016, 11, 749-762.	4.1	9
11	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16068.	4.1	48
12	Gene based therapies for kidney regeneration. European Journal of Pharmacology, 2016, 790, 99-108.	3.5	7
13	The CD8 Tâ€cell response during tolerance induction in liver transplantation. Clinical and Translational Immunology, 2016, 5, e102.	3.8	15
14	Innovating immune tolerance induction for haemophilia. Haemophilia, 2016, 22, 31-35.	2.1	12
15	Clinical development of gene therapy: results and lessons from recent successes. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16034.	4.1	183
16	Liver-Specific Allergen Gene Transfer by Adeno-Associated Virus Suppresses Allergic Airway Inflammation in Mice. Human Gene Therapy, 2016, 27, 631-642.	2.7	7
17	Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy, 2016, 27, 43-59.	2.7	44
18	In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cellular Immunology, 2016, 301, 18-29.	3.0	34

#	Article	IF	Citations
19	The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Molecular Therapy, 2017, 25, 880-891.	8.2	50
20	Large scale studies assessing antiâ€factor <scp>VIII</scp> antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology, 2017, 178, 20-31.	2.5	10
21	Gene Therapy for Hemophilia. Molecular Therapy, 2017, 25, 1163-1167.	8.2	74
22	Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery ofSleeping BeautyTransposons: Implications for Non-Viral Gene Therapy of Systemic Disease. Human Gene Therapy, 2017, 28, 551-564.	2.7	8
23	Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies. Molecular Therapy - Methods and Clinical Development, 2017, 6, 124-134.	4.1	16
24	Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. Frontiers in Psychiatry, 2017, 8, 46.	2.6	21
25	Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. Frontiers in Immunology, 2017, 8, 1604.	4.8	28
26	Gene therapy for hemophilia. Pediatric Blood and Cancer, 2018, 65, e26865.	1.5	30
27	Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis. Molecular Therapy, 2018, 26, 173-183.	8.2	64
28	Stem cells as delivery vehicles for regenerative medicine-challenges and perspectives. World Journal of Stem Cells, 2018, 10, 43-56.	2.8	60
29	Gene therapy and type 1 diabetes mellitus. Biomedicine and Pharmacotherapy, 2018, 108, 1188-1200.	5.6	58
30	Emerging therapies for hemophilia: controversies and unanswered questions. F1000Research, 2018, 7, 489.	1.6	29
31	Preparation of Complexes between Ovalbumin Nanoparticles and Retinoic Acid for Efficient Induction of Tolerogenic Dendritic Cells. Analytical Sciences, 2018, 34, 1243-1248.	1.6	1
32	How Simian Virus 40 Hijacks the Intracellular Protein Trafficking Pathway to Its Own Benefit â€¦ and Ours. Frontiers in Immunology, 2018, 9, 1160.	4.8	21
33	Gene therapy for hemophilia: what does the future hold?. Therapeutic Advances in Hematology, 2018, 9, 273-293.	2.5	79
34	Gene Therapy for Pompe Disease: The Time is now. Human Gene Therapy, 2019, 30, 1245-1262.	2.7	20
35	Gene therapy for hemophilia: Progress to date and challenges moving forward. Transfusion and Apheresis Science, 2019, 58, 602-612.	1.0	23
36	Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 12, 184-201.	4.1	39

#	Article	IF	Citations
37	An update on gene therapy for lysosomal storage disorders. Expert Opinion on Biological Therapy, 2019, 19, 655-670.	3.1	38
38	FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice. Blood Advances, 2019, 3, 825-838.	5.2	24
39	Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors. Molecular Therapy - Methods and Clinical Development, 2019, 12, 223-232.	4.1	15
40	Liver induced transgene tolerance with AAV vectors. Cellular Immunology, 2019, 342, 103728.	3.0	45
41	Complexity of immune responses to AAV transgene products â€“ Example of factor IX. Cellular Immunology, 2019, 342, 103658.	3.0	37
42	A Molecular Revolution in the Treatment of Hemophilia. Molecular Therapy, 2020, 28, 997-1015.	8.2	66
43	Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy, 2020, 28, 709-722.	8.2	382
44	Role of Liposomes-Based Stem Cell for Multimodal Cancer Therapy. Stem Cell Reviews and Reports, 2020, 16, 103-117.	3.8	15
45	B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin. Frontiers in Immunology, 2020, 11, 1293.	4.8	16
46	Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A. Frontiers in Immunology, 2020, 11, 618.	4.8	22
47	Escape or Fight: Inhibitors in Hemophilia A. Frontiers in Immunology, 2020, 11, 476.	4.8	8
48	Inhibitorsâ€"Recent insights. Haemophilia, 2021, 27, 28-36.	2.1	6
49	Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies. Frontiers in Immunology, 2021, 12, 658038.	4.8	31
50	Secondary failure: immune responses to approved protein therapeutics. Trends in Molecular Medicine, 2021, 27, 1074-1083.	6.7	9
51	Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders. Open Life Sciences, 2021, 16, 431-441.	1.4	2
52	Direct recognition of hepatocyte-expressed MHC class I alloantigens is required for tolerance induction. JCI Insight, 2018, 3, .	5.0	11
53	Ubiquitous Over-Expression of Chromatin Remodeling Factor SRG3 Ameliorates the T Cell-Mediated Exacerbation of EAE by Modulating the Phenotypes of both Dendritic Cells and Macrophages. PLoS ONE, 2015, 10, e0132329.	2.5	8
55	Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. International Journal of Molecular and Cellular Medicine, 2020, 9, 33-50.	1.1	4

#	Article	IF	Citations
56	Immunological barriers to haematopoietic stem cell gene therapy. Nature Reviews Immunology, 2022, 22, 719-733.	22.7	22
57	Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice. Frontiers in Immunology, 2021, 12, 752916.	4.8	7
61	Gene Therapy for Pediatric Neurologic Disease. Hematology/Oncology Clinics of North America, 2022, , .	2.2	0
62	IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice. Molecular Therapy, 2022, 30, 3552-3569.	8.2	16
63	Immune Complications and their Management in Inherited and Acquired Bleeding Disorders. Blood, 0, , .	1.4	6
64	Advanced drug delivery systems involving lysosomal storage disorders for Schinder disease and other disorders. , 2022, , 281-299.		0
65	Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of TÂcell epitope usage or mouse strain background. Molecular Therapy - Methods and Clinical Development, 2023, 28, 177-189.	4.1	4
66	Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells. Molecular Therapy - Nucleic Acids, 2023, 32, 322-339.	5.1	1
67	Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy. AAPS Journal, 2023, 25, .	4.4	6
68	<scp>MiR133b</scp>â€mediated inhibition of <scp>EGFRâ€PTK</scp> pathway promotes <scp>rAAV2</scp> transduction by facilitating intracellular trafficking and augmenting secondâ€strand synthesis. Journal of Cellular and Molecular Medicine, 2023, 27, 2714-2729.	3.6	1